Accelerating Medicine Partnership in Alzheimer’s Disease

AMP-AD is a public private partnership designed to use systems biology to identify novel targets for AD treatment.

Accelerating Medicine Partnership in Alzheimer’s Disease

The Accelerating Medicine Partnership for Alzheimer’s Disease (AMP-AD) Knowledge Portal is a premier repository and workspace for multi-omic data generated through the AMP-AD consortia – a public- private partnership between academic research groups, industry partners, and non-profit partners. The primary goal of the consortia is to generate and test hypotheses to identify new targets for intervention in the treatment of Alzheimer’s disease. Deposited data includes gene expression, genotype, methylation, CHiP-Seq, DNA methylation, miRNA profiles, and clinical data, among others from human participants as well as animal and cell line model systems. Data is publically released on an aggressive schedule, with data releases occurring every quarter, starting in March 2015.

Learn more about the datasets, collaborators or external research projects by visiting the AMP-AD Knowledge Portal on Synapse.


Other Collaborative Science research studies

Accelerating Medicine Partnership in Alzheimer’s Disease

AMP-AD is a public private partnership designed to use systems biology to identify novel targets for AD treatment.

Learn More

The ICGC-TCGA Whole Genome Pan-Cancer Analysis Working Group

The Pan-Cancer Analysis of Whole Genomes (PCAWG) is an effort to combine all ICGC and TCGA whole genome sequencing data to collaboratively attain an integrated understanding of cancer by deriving insights across tumor types.

Learn More

SYNODOS

Synodos is a first-of-its-kind Nuerofibromatosis research collaboration dedicated to defeating the rare genetic disorder neurofibromatosis.

Learn More